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To evaluate the efﬁcacy and safety of anti-NGF antibody treatment in hip and knee osteoarthritis (OA), a
systematic review and meta-analysis was undertaken utilizing the criteria described by the Cochrane
collaboration. Both published and unpublished trials were identiﬁed for tanezumab, fulranumab and
fasinumab in hip and knee OA; sponsors were contacted to provide and conﬁrm data. Study quality was
assessed by Jadad criteria; efﬁcacy and safety data were extracted independently by two individuals and
meta-analyses were performed using Revman 5.2. 13 randomized, controlled trials were identiﬁed: 10 of
tanezumab, two of fulranumab and one with fasinumab. All agents demonstrated superiority in efﬁcacy
compared to placebo. The highest doses in the phase II studies of tanezumab had a standardized effect
size for WOMAC pain of 0.73 (CI, 0.51, 0.95). Subsequent phase III studies of tanezumab and phase II
studies of fulranumab and fasinumab reported standardized effect sizes for WOMAC pain of 0.15e0.5,
with no clear distinction among dose levels. Tanezumab compared to NSAIDs and opioids showed
greater efﬁcacy with a standardized effect size for WOMAC pain of 0.23 (CI 0.17e0.29). WOMAC function
and PGA results were similar to WOMAC pain. Safety, determined by odds ratios of withdrawals from
studies due to adverse events (AEs), was better at the lower doses than higher doses and similar among
all agents. These results demonstrate that antibodies to NGF provide efﬁcacy in OA and that general
safety at the lower doses appears similar to placebo. Additional data on both efﬁcacy and safety of these
antibodies are needed to deﬁne the optimal dose to maximize beneﬁt to risk.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Treatment of chronic pain continues to be one of the major
challenges in clinical medicine. An estimated 116million Americans
are burdened by chronic pain, resulting in an annual cost of be-
tween $560e$635 billion1. Pain is the cardinal manifestation of
osteoarthritis (OA), yet the least well studied2. Despite the avail-
ability of a wide spectrum of non-pharmacologic and pharmaco-
logic options, for many people with OA, chronic pain is not
adequately controlled and leads to reduced activity and a markedly
diminished quality of life3,4. The development of non-surgical
interventions that are more effective and associated with fewer
untoward effects than existing therapies remains a priority.
With the rapid growth during the past 10e20 years in our basic
understanding of pain mechanisms, a large number of targets toT.J. Schnitzer, Northwestern
611, USA. Tel: 312-503-2315;
. Schnitzer), julia.marks@
ternational. Published by Elsevier Lpotentially modulate nociceptive and neuropathic pain responses
have been identiﬁed5. Nerve growth factor (NGF), a member of the
neurotrophin family of molecules, was discovered in the 1950's by
Levi-Montalcini and Cohen6; subsequent research demonstrated
that NGF is critical for normal development of sympathetic neu-
rons and sensory neurons responsible for nociception and tem-
perature sensation. In adults, withdrawal of NGF results in
decreased sensitivity of these peripheral nociceptors and a
reduction in neuropeptide levels7. Additional evidence that NGF
plays a role in pain in man comes from studies in which NGF
injected into the skin was shown to result in pain8, and from a
genetic pain deﬁciency syndrome, congenital insensitivity to pain
and anhidrosis (CIPA) in which abnormalities in the gene for
neurotrophic tyrosine kinase receptor type 1 (trkA), a high-afﬁnity
receptor of NGF, prevented normal binding9,10. The mechanisms by
which NGF may affect pain remains an area of active investigation.
NGF is known to bind to two receptors on peripheral nociceptors,
trkA and p75, activating a signaling pathway of intracellular ki-
nases which can eventually lead to neurite outgrowth and sensi-
tization of these neurons11,12.td. All rights reserved.
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in animals and man provided yet further evidence for the central
importance of NGF in pain13,14. Phase I data with anti-NGF mono-
clonal antibodies in OA painwere reported in 200515,16 and a phase
II study with the monoclonal antibody tanezumab, published in
2010, demonstrated dose-dependent efﬁcacy and safety in a people
with moderate to severe pain due to knee OA17. Subsequently, an
extensive phase III development program was initiated to study in
greater detail the efﬁcacy and safety of tanezumab. Other mono-
clonal antibodies directed at NGF have also been developed and
two, fulranumab and fasinumab, have had initial studies reported
in OA18,19. The development programs in OA of all anti-NGF
monoclonal antibodies were put on clinical hold by the U.S. Food
and Drug Administration (FDA) in 2010 due to the emergence of
joint adverse effects20, discussed elsewhere in this issue of OAC by
Hochberg and therefore not a speciﬁc focus of the current review21.
This report provides an update on the clinical studies with anti-NGF
monoclonal antibodies in the form of a systematic review and
meta-analysis of the efﬁcacy and general safety of tanezumab,
fulranumab and fasinumab, utilizing data available from the cur-
rent published literature and unpublished sources.
Methods
Study selection
Randomized clinical trials studying the administration of anti-
NGF for the treatment of OA of the knee or hip were selected for
analysis. Eligible studies were identiﬁed by searching PubMed and
Embase using the following keywords: tanezumab, fulranumab,
fasinumab, anti-NGF, NGF, osteoarthritis, or OA. Additionally, a list
of available studies was obtained through contact with the de-
velopers of tanezumab, fulranumab and fasinumab (Pﬁzer, Janssen
and Regeneron, respectively). No language, publication date, or
publication status restrictions were imposed; participants of any
age, duration of disease, and non-steroidal anti-inﬂammatory drug
(NSAID) or opioid use were considered.
Data collection process/data items
Data were extracted from articles independently by two re-
viewers using a standardized template. Information was extracted
from each included trial on: (1) characteristics of trial participants
(including age, gender, years since diagnosis, KellgreneLawrence
grade and knee vs hip OA stratiﬁcation, if applicable), and the trial's
inclusion and exclusion criteria; (2) type of intervention (including
type of anti-NGF, dose, duration, and frequency of NSAID use; vs
placebo or vs placebo plus NSAID; or vs another treatment
method); (3) type of outcome measure (including change in
Western Ontario and McMaster [WOMAC] Osteoarthritis Index
subscales, patient's global assessment [PGA] and index knee pain at
each deﬁned endpoint vs reported baseline measures); (4) safety
data (including incidence of AEs and serious adverse events [SAEs],
and discontinuations due to AEs). Missing data were provided by
the study sponsors and quality assurance was performed by study
sponsors to verify accuracy of extracted data.
Risk of bias within studies
To ascertain the validity of the thirteen randomized trials, the
quality of each of the studies was assessed using the Jadad Scale
score22, which gives a maximal score of 5 if all criteria are met.
These criteria take into consideration the adequacy of randomiza-
tion, and blinding of patients, health care providers, data collectors,
and outcome assessors, as well as description of dropouts andwithdrawals. The appropriateness of allocation concealment for
each of the trials was also assessed.
Summary measures
The meta-analysis was performed using Review Manager 5.223.
The primary outcome measure was mean change in WOMAC pain
for each treatment type and dose vs placebo, comparing study
prespeciﬁed endpoint values with baseline values. We used a sta-
tistical model of standard mean difference (95% conﬁdence interval
[CI]), or Hedges' adjusted g, which is very similar to Cohen's d, but
includes an adjustment for small sample bias24. A random effects
model and inverse variancewere used to calculate the standardized
effect sizes of each group. Secondary outcomes included change in
WOMAC physical function and PGA compared to baseline, as well as
safety outcomes. WOMAC subscale scores were considered on a
numeric rating scale (NRS) of 0e10; WOMAC scores that were re-
ported on a 0e100mm scale weremultiplied by 0.1 to convert to an
11-point NRS for ease of comparison. Similarly, PGA scores were
considered on a 5-point Likert scale; PGA scores that were reported
on a 0e100 mm scale were multiplied by 0.04 to convert to a
5-point scale. Our analyses uses least squares mean ± standard
deviation (SD) for all mean change data for tanezumab, and un-
adjusted mean ± SD for fasinumab and fulranumab data, as re-
ported in the individual trials. These data were provided and/or
veriﬁed by the study sponsor, and, as needed, SD was calculated
based on reported standard errors (SEs) and sample size.
The safety data extracted from the publications were veriﬁed by
the study sponsor and any missing data were provided. A meta-
analysis of the safety outcomes of discontinuations due to AEs
and incidence of SAEs was performed with determination of
Mantel-Haenszel odds ratio using a random effects model. The
odds ratios for both outcomes were calculated based on the num-
ber of events that occurred within each treatment arm relative to
the number of subjects within each arm, as compared to placebo.
Synthesis of results
The response of each dosing arm for each study was compared
to the placebo arm of the same study. Data were grouped by
treatment type and then by dosage. The studies that used tanezu-
mab were divided into two groups: placebo-controlled trials and
active-comparator trials. The tanezumab treatment arms that were
included in the efﬁcacy analysis for the placebo-controlled trials
were tanezumab 2.5 mg, tanezumab 5 mg, and tanezumab 10 mg,
in the case of the phase III data, and tanezumab 10 mg/kg, tanezu-
mab 25 mg/kg, tanezumab 50 mg/kg, tanezumab 100 mg/kg, and
tanezumab 200 mg/kg, for the phase II data from Lane et al.17 and
Nagashima et al.25. The phase II and phase III tanezumab data were
considered separately, as tanezumab was dosed in the phase II
studies on a mg/kg basis, whereas the phase III trials used a standard
dosing method of ﬁxed milligram amounts. Since there was no
simple means of combining dose groups between phase II and
phase III trials, we felt that it was most appropriate to consider
these data separately.
The data from Balanescu et al.26 and Schnitzer et al., 201427 were
included in the active-controlled trials and included the use of oral
diclofenac sustained release (DSR), and celecoxib or naproxen,
respectively. The Spiering et al. trial28 and the two Ekman et al.
trials29 were included in both groups. The active-comparator trials
all involved only tanezumab 5 mg and tanezumab 10 mg arms
except for the Balanescu et al. study, in which tanezumab 2.5 mg
was also included. In the studies of fulranumab, treatment arms
included placebo, fulranumab 1mgQ4wk, fulranumab 3mgQ8wk,
fulranumab 3mgQ4wk, fulranumab 6mgQ8wk, or fulranumab
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numab 9mgQ4wk (Mayorga et al.30). For the study with fasinumab
(Tiseo et al.19), the treatment arms included placebo, fasinumab
0.03 mg/kg, fasinumab 0.1 mg/kg, and fasinumab 0.3 mg/kg.
The standard mean difference for each treatment type and dose
was assessed for the individual studies and dosing groups, as well
as overall. The presence or absence of heterogeneity and the degree
of heterogeneity of each treatment type and dose is reported as c2
and I2, respectively. c2 values that had a P-value of 0.05 were
considered to be statistically signiﬁcant.
Results
Study characteristics
Thirteen multicenter trials for OA of the knee or OA of the hip or
knee met our inclusion and exclusion criteria18,19,25e34. All were
sponsored by pharmaceutical companies. The Mayorga et al. trial
was the only unpublished trial and was included in the systematic
review in an effort to present all available data and avoid any
publication bias. All thirteen studies were considered to be high
quality trials and were given a Jadad Scale score of either 4 or 5 out
of 5 (See Supplemental Table 1). All thirteen trials used an inter-
active voice response system (IVRS) to assign subjects to treatment
groups in a blinded fashion andwere thereby considered to have an
adequate method of allocation concealment. The duration of each
trial ranged from 8 weeks to 32 weeks. The studies had different
age criteria for inclusion (18 years of age or between ages of
35e80 years), and a majority required subjects to have OA with a
KellgreneLawrence grade of2 and aWOMAC Pain or NRS score of
4 or 5. Both Ekman studies and Schnitzer et al., 2014 also listed
body mass index (BMI) 39 kg/m2 as inclusion criteria. Other
common criteria included inadequate relief from non-opiate
medication, candidacy for surgical interventions, and stable
NSAID or opioid use. (See Table I for details).
The included studies involved 8606 participants, of which 8580
were randomized and have reported baseline demographics. Seven
studies include randomized participants with OA of the knee
(n ¼ 2532), while the remaining ﬁve studies include individuals
with OA of the knee or hip (n ¼ 6048). Overall, participants had a
mean age of 60.9 years and mean duration of OA of 7.2 years.
Gender, mean age, duration of disease, and KellgreneLawrence
grades are reported in Table II.
Schnitzer et al., 2011 was excluded from the analyses, as it was a
long-term safety extension study of Lane et al. and there was no
comparator group (only tanezumab was studied). The primary
outcome measure for the remaining 12 studies was change in
WOMAC pain and/or WOMAC physical function and PGA, with the
exception of Nagashima et al., Sanga et al., and Tiseo et al., whose
primary outcome was various index knee pain scores. WOMAC
subscales and PGA values were secondary outcome measures in
these studies. Values of the outcome measures used in this meta-
analysis were taken at study endpoints, which were 8 weeks (3),
12 weeks (2), and 16 weeks (7).
There were 10 placebo-controlled trials, seven involving tane-
zumab, two with fulranumab and one with fasinumab. In four
placebo-controlled studies there was also an active control, three
studies of tanezumab (oxycodone, Spierings et al.; naproxen,
Ekman et al. a and b) and one study with fulranumab (oxycodone,
Mayorga et al.). There were two additional studies that had an
active control but no placebo arm: Balenscu et al., in which tane-
zumab plus diclofenac was compared to diclofenac and Schnitzer
et al., 2014, in which tanezumab and NSAID (naproxen and cele-
coxib as separate arms) and tanezumab alone were compared to
NSAID (naproxen and celecoxib as separate arms).Efﬁcacy: WOMAC pain
Placebo-controlled trials
Data from the 12 efﬁcacy trials were divided by type of anti-NGF
therapy; additionally, the phase II and phase III tanezumab data
were considered separately because of the difference in approach to
dose determinationwith phase II studies administering tanezumab
on a mg/kg basis and the phase III studies administering study drug
at ﬁxed doses. There were two phase II studies of tanezumab (Lane
et al. and Nagashima et al.) which demonstrated standardized effect
sizes ranging from 0.31 to 0.94 with ﬁve different dose groups
(10 mg/kg, 25 mg/kg, 50 mg/kg, 100 mg/kg, and 200 mg/kg) over a
20-fold dose range. When comparing the different dosage sub-
groups of the phase II studies of tanezumab, a moderately large
degree of heterogeneity was found (I2¼ 42.6%, P¼ 0.14). To explore
this further, we systematically examined different dose groups for
heterogeneity and combined groups when heterogeneity was not
found, starting from both the highest and lowest dose groups, and
then comparing the combined groups. With this approach, the two
highest dose groups (200 mg/kg and 100 mg/kg) could be combined
as could the 3 lowest dose groups, and their comparison (combined
high dose groups vs combined low dose groups) supported a sig-
niﬁcant group difference, c2 ¼ 7.06, P ¼ 0.008. Both lower and
higher dose subgroupswere statistically signiﬁcantly different from
placebo (P < 0.001), (See Fig. 1).
The 5 placebo-controlled phase III tanezumab studies evaluated
a narrower dose range (2.5 mg, 5 mg, and 10 mg) and reported a
correspondingly narrower range of standardized effect sizes, from
0.25 to 0.61, all being statistically signiﬁcantly different from pla-
cebo (P < 0.001). No heterogeneity was observed among these
three dose subgroups (I2 ¼ 0, Fig. 2). When meta-analyses were
limited to the two studies in which all three dose groups were
studied, comparison of the 10 mg dose group (standardized effect
size ¼ 0.51) with the 2.5 mg dose group (standardized effect
size ¼ 0.35) demonstrated a non-signiﬁcant difference (c2 ¼ 1.44,
P ¼ 0.23; I2 ¼ 30.4%) and likewise no statistically signiﬁcant dif-
ference between the 5 mg and 2.5 mg dose groups.
The fulranumab study conducted by Sanga et al. evaluated a
5-fold range of exposure (2 mge10 mg over 8 weeks) using two
different dosing frequencies (every 4 weeks and every 8 weeks).
Mayorga et al. evaluated fulranumab at 3 mg and 9 mg doses
administered every 4 weeks. Because of the limited number of
studies, a synthesis based on dose levels was not attempted.
Considering all doses investigated, there was an overall standard-
ized effect size of 0.26 (0.12, 0.40), P < 0.001 including both studies,
and 0.34 (0.20, 0.48), P < 0.001 if the Mayorga study is excluded
(See Table III), as the majority of subjects were withdrawn pre-
maturely due to the FDA imposed clinical hold. Fasinumab was
studied over a 10-fold dose range (0.03 mg/kg to 0.30 mg/kg fasi-
numab) with no heterogeneity between doses but a numeric dif-
ference between the lowest dose in comparison to the two highest
doses, with standardized effect sizes ranging from 0.15 to 0.42 and
an overall standardized effect size of 0.31 (0.09, 0.53), P ¼ 0.006.
Active-control trials
Both tanezumab and fulranumab were investigated in active-
controlled trials. Four studies compared tanezumab monotherapy
to an active agent (oxycodone, naproxen or celecoxib). Both the
5 mg and 10 mg dosage groups of tanezumab monotherapy
demonstrated superior efﬁcacy to comparator active compounds,
with a standardized effect sizes of 0.24(0.15, 0.32) and 0.22(0.13,
0.30), respectively, with P < 0.001 for both. Comparison of tane-
zumab plus NSAID to NSAID alone demonstrated greater efﬁcacy
for the combination with both tanezumab 5 mg and tanezumab
10 mg with standardized effect sizes of 0.28 (0.17, 0.39) and 0.35
Table I
Summary of study design
Study No. of subjects Inclusion criteria Length Primary end points
Balanescu et al., 2013 607 Knee or hip OA
WOMAC pain  4
DSR 150 mg/day
16 weeks Change in WOMAC pain
Change in WOMAC physical function
Change in PGA
16 weeks
Brown et al., 2012 697 Knee OA
WOMAC pain  5
WOMAC physical function  4
PGA  3
Inadequate relief from non-opiate medication
or candidacy for surgical interventions
32 weeks Change in WOMAC pain
Change in WOMAC physical function
Change in PGA
16 weeks
Brown et al., 2013 627 Knee OA
Inadequate relief from non-opiate medication
or candidacy for surgical interventions
32 weeks Change in WOMAC pain
Change in WOMAC physical function
Change in PGA
16 weeks
Ekman et al., 2011 (a, b) 1668 (828, 840) Knee or hip OA
KellgreneLawrence grade of 2
WOMAC pain  5
WOMAC physical function  4
PGA very poor, poor, fair
BMI  39 kg/m2
18 years of age or older
24 weeks Change in WOMAC pain
Change in WOMAC physical function
Change in PGA
16 weeks
Lane et al., 2010 450 Knee OA
KellgreneLawrence grade of 2
Inadequate relief from non-opiate medication
or candidacy for surgical interventions
40e75 years of age
16 weeks Index knee pain while walking
Change in PGA
16 weeks
Mayorga et al., 2014 196 Knee OA
NRS score of 5
Around-the-clock NSAID or opioid use with
inadequate relief
40e80 years of age
16 weeks Responder rate as given by NRS
Change in WOMAC subscales
Change in PGA
12 weeks
Nagashima et al., 2011 83 Knee OA
KellgreneLawrence grade of 2
Inadequate relief from non-opiate medication
or candidacy for surgical interventions
35e75 years of age
13e17 weeks Index knee pain while walking
Index knee pain in the past 24 h
Current index knee pain
Change in WOMAC subscales
8 weeks
Sanga et al., 2013 466 Knee or hip OA
KellgreneLawrence grade of 2
Stable NSAID or opioid use
40e80 years of age
12 weeks Pain intensity score
12 weeks
Schnitzer et al., 2011 281 Knee OA
Inadequate relief from non-opiate medication
or candidacy for surgical interventions
40e75 years of age
8 weeks Safety
8 weeks
Schnitzer et al., 2014 2700 Knee or hip OA
KellgreneLawrence grade of 2
WOMAC pain  4
WOMAC physical function  4
PGA very poor, poor, fair
Stable NSAID use with some effect
BMI  39 kg/m2
18 years of age or older
16 weeks Change in WOMAC pain
Change in WOMAC physical function
Change in PGA
16 weeks
Spierings et al., 2013 614 Knee or hip OA
KellgreneLawrence grade of 2
WOMAC pain  5
WOMAC physical function  4
PGA very poor, poor, fair
Regular use of analgesics other than acetaminophen
8 weeks Change in WOMAC pain
8 weeks
Tiseo et al., 2014 217 Knee OA
KellgreneLawrence grade of 2 or 3
NRS  4
40e75 years of age
24 weeks Safety
Change in NRS
Change in WOMAC subscales
16 weeks
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Fig. 1(A) & (B)).
For fulranumab, a single study was done and showed a nu-
merical difference from the active control (oxycodone), although no
differentiation was seen between either fulranumab dose and
placebo in the same study.Efﬁcacy: WOMAC function and patient's global assessment
Data for each of these outcome measures were also evaluated
and demonstrated results similar to those for WOMAC pain. These
data and synthesis of results are included in the supplementary
materials (See Supplemental Fig. 2(A) & (B)).
Table II
Study participant baseline characteristics
Study Arms Subjects per arm Gender, male (%) Mean age Mean years
since diagnosis
KellgreneLawrence grade
2 3 4
Balanescu et al., 2013 Placebo þ DSR 152 22.4 62.3 6.1 44.7 44.7 10.5
Tanezumab 2.5 mg þ DSR 157 22.9 62.1 6.1 49.0 43.3 7.6
Tanezumab 5 mg þ DSR 150 26.7 62.2 6.7 42.7 47.3 10.0
Tanezumab 10 mg þ DSR 145 17.2 63.1 6.6 50.3 42.8 6.9
Brown et al., 2012 Placebo 172 30.8 62.2 8.2 39.5 47.7 12.8
Tanezumab 2.5 mg/day 172 45.3 60.8 7.3 37.2 43.0 18.0
Tanezumab 5 mg/day 172 41.3 62.1 7.5 37.2 51.7 10.5
Tanezumab 10 mg/day 174 39.1 61.4 9.5 40.8 44.3 14.9
Brown et al., 2013 Placebo 155 33.5 61.9 5.6 47.1 36.1 16.8
Tanezumab 2.5 mg/day 155 34.8 62.4 6.0 45.8 34.2 20.0
Tanezumab 5 mg/day 154 40.3 61.8 6.3 46.8 35.1 17.5
Tanezumab 10 mg/day 157 43.9 63.3 5.6 42.7 36.9 20.4
Ekman et al., 2014a Placebo 208 42.3 60.9 9.0 42.8 43.8 13.5
Tanezumab 5 mg/day 206 40.8 61.1 7.9 36.9 52.4 10.7
Tanezumab 10 mg/day 208 38.5 61.1 8.5 47.1 43.3 9.6
Naproxen 500 mg bid 206 37.4 61.4 7.2 48.1 43.2 8.7
Ekman et al., 2014b Placebo 209 34.9 60.1 6.3 51.2 37.8 10.5
Tanezumab 5 mg/day 211 36.5 59.8 6.4 49.3 36.5 14.2
Tanezumab 10 mg/day 209 38.8 59.2 6.8 48.3 34.4 17.2
Naproxen 500 mg bid 211 35.5 60.3 7.7 52.1 39.8* 8.1
Lane et al., 2010 Placebo 74 43.0 58.1 25.0 75.0*
Tanezumab 10 mg/kg 74 34.0 58.3 29.0 71.0*
Tanezumab 25 mg/kg 74 32.0 59.9 31.0 69.0*
Tanezumab 50 mg/kg 74 50.0 60.4 39.0 61.0*
Tanezumab 100 mg/kg 74 41.0 57.1 30.0 70.0*
Tanezumab 200 mg/kg 74 46.0 58.4 26.0 74.0*
Mayorga et al. Placebo 48 47.9 59.2
Fulranumab 3mgQ4wk 48 37.5 58.8
Fulranumab 9mgQ4wk 50 40.0 58.6
Oxycodone CR 10-50 q12 50 50.0 60.9
Nagashima et al., 2011 Placebo 16 31.3 59.4 10.1 50.0 43.8 6.3
Tanezumab 10 mg/kg 15 33.3 59.3 3.8 46.7 53.3 0.0
Tanezumab 25 mg/kg 15 46.7 57.3 5.4 60.0 40.0 0.0
Tanezumab 50 mg/kg 15 26.7 60.7 5.0 93.3 6.7 0.0
Tanezumab 100 mg/kg 16 25.0 58.1 3.1 68.8 31.3 0.0
Tanezumab 200 mg/kg 6 16.7 60.0 7.4 50.0 50.0 0.0
Sanga et al., 2013 Placebo 78 44.9 61.3
Fulranumab 1mgQ4wk 77 41.6 61.2
Fulranumab 3mgQ8wk 76 40.8 60.5
Fulranumab 3mgQ4wk 79 41.8 60.8
Fulranumab 6mgQ8wk 78 39.7 60.7
Fulranumab 10mgQ8wk 78 46.2 61.4
Schnitzer et al., 2011 Placebo 42 45.2 57.9
Tanezumab 10 mg/kg 47 34.0 59.2
Tanezumab 25 mg/kg 49 28.6 60.7
Tanezumab 50 mg/kg 49 42.9 60.2
Tanezumab 100 mg/kg 47 38.3 58.5
Tanezumab 200 mg/kg 47 46.8 59.4
Schnitzer et al., 2014 Placebo þ NSAID 539 28.0 61.3 7.5 36.5 40.3 23.2
Tanezumab 5 mg/day 541 27.5 61.9 7.3 33.5 35.3 31.2
Tanezumab 10 mg/day 542 27.7 62.0 7.1 34.5 37.5 28.0
Tanezumab 5 mg/day þ NSAID 536 32.3 61.7 7.0 34.2 39.6 26.0
Tanezumab 10 mg/day þ NSAID 542 31.9 61.3 7.4 29.7 40.2 30.1
Spierings et al., 2013 Placebo 141 34.8 57.2 7.4 47.5 39.7 12.8
Tanezumab 5 mg/day 161 40.4 57.8 7.6 48.4 37.3 14.3
Tanezumab 10 mg/day 150 37.3 57.0 7.5 48.7 36.7 14.7
Oxycodone CR 10e40 q12 h 158 37.3 57.6 6.2 50.6 34.8 14.6
Tiseo et al., 2014 Placebo 55 21.8 59.1
Fasinumab 0.03 mg/kg 53 39.6 59.0
Fasinumab 0.1 mg/kg 53 32.1 60.3
Fasinumab 0.3 mg/kg 54 31.5 58.8
* Kellgren-Lawrence grade 3 or 4.
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Placebo-controlled trials
A summary of the number of withdrawals from the study in each
treatment group due to AEs for each trial is given in Table IV. For the
safety analyses, each anti-NGF agent was considered separately
initially and then all studies combined. For tanezumab, comparing
all groups of subjects receiving tanezumab as monotherapy toplacebo, the odds ratio for withdrawals due to AEs was 1.50 (0.94,
2.38), P ¼ 0.09. To investigate the relationship of this safety
parameter with dose, the phase II and phase III studies were
analyzed separately. Because of the small number of events re-
ported in the phase II studies, a quantitative analysis was not per-
formed but the highest doses of tanezumab were associated with
the greatest frequency of withdrawal due to AEs. For the phase 3
studies, the overall odds ratio for withdrawal due to AEs was 1.41
Fig. 1. Phase II efﬁcacy data; standard mean change [95% CI] in WOMAC pain compared to baseline by dosing group.
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tanezumab dose groups, 2.5 mg and 5.0 mg, had similar odds ratios
for withdrawal due to AEs of 1.23 (0.50, 3.02) and 1.09 (0.55, 2.16),
respectively, which did not differ statistically from placebo,
whereas the tanezumab 10 mg dose group had an odds ratio of 1.92
(1.20, 3.09), which was statistically different from placebo
(P ¼ 0.007). With regard to SAEs, there was little difference among
the dose groups; overall, the phase III treatment groups yielded an
odds ratio of 0.99 (0.67, 1.45) compared to placebo.Fig. 2. Phase III efﬁcacy data; standard mean change [95% CI]Meta-analysis of the withdrawals due to AEs in the fulranumab
trial showed no statistically signiﬁcant effect between the placebo
and treatment arms. Quantitative analyses were necessarily
imprecise due to the small sample sizes and few reported events,
with an estimated odds ratio of 1.77 (0.74, 4.22) for the fulranumab
groups compared to placebo. Evaluation of fasinumab safety was
also limited with only one study and few events to analyze. The
odds ratio for withdrawal due to AEs in the fasinumab groups
compared to placebo was 1.53 (0.50, 4.73) with the highest dosein WOMAC pain compared to baseline by dosing group.
Table III
Summary of fulranumab and fasinumab efﬁcacy data vs placebo
Study, year Study arm Mean change SD N Weight (%) Effect size 95% CI
Mayorga et al., 2014 Placebo 3.0 2.39 44
Fulranumab 3mgQ4wk 2.9 2.42 45 9.9 0.04 [e0.46, 0.37]
Fulranumab 9mgQ4wk 2.9 2.44 47 10.1 0.04 [e0.45, 0.37]
Sanga et al., 2013 Placebo 1.8 2.02 78
Fulranumab 1mgQ4wk 2.2 2.48 77 16.1 0.18 [e0.14, 0.49]
Fulranumab 3mgQ8wk 2.6 2.34 76 15.8 0.36 [0.05, 0.68]
Fulranumab 3mgQ4wk 2.8 2.27 79 16.0 0.46 [0.15, 0.78]
Fulranumab 6mgQ8wk 2.5 2.48 78 16.1 0.31 [e0.01, 0.62]
Fulranumab 10mgQ8wk 2.6 2.14 78 16.0 0.38 [0.07, 0.70]
Total (95% CI) 602 100.0 0.26 [0.12, 0.40]
Tiseo et al., 2014 Placebo 2.4 2.18 55
Fasinumab 0.03 mg/kg 2.7 1.89 53 33.6 0.15 [e0.23, 0.52]
Fasinumab 0.1 mg/kg 3.4 2.53 53 32.9 0.42 [0.04, 0.80]
Fasinumab 0.3 mg/kg 3.2 2.24 54 33.5 0.36 [e0.02, 0.74]
Total (95% CI) 115 100.0 0.31 [0.09, 0.53]
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incidence of SAEs for both fulranumab and fasinumab were too
sparse to evaluate meaningfully. There were no signiﬁcant imbal-
ances seen in incidence of SAEs between the active and placebo
groups for either agent.
The odds ratio of withdrawals due to AEs comparing all groups
of subjects receiving anti-NGF monotherapy to placebo was 1.50
(1.01, 2.23), P ¼ 0.04 (See Fig. 3), similar to that of tanezumab
monotherapy vs placebo given above.
Active-control trials
In the active-controlled studies, tanezumab monotherapy
compared to active agent (oxycodone, NSAID) demonstrated
extreme heterogeneity for both tanezumab dose groups when all 4
studies were considered. Much of the heterogeneity was elimi-
nated with removal of the Spierings et al. study which included
oxycodone as the comparator. Evaluation of tanezumab with only
NSAID comparators demonstrated an odds ratio 1.09 (0.71, 1.68)
which was not statistically signiﬁcant. Spierings et al. had four to
eight times the number of withdrawals due to AEs in the oxycodone
group compared to tanezumab groups, and therefore favored
treatment with tanezumab at both the 5 mg and 10 mg dose. The
incidences of SAEs in both trials were the same for the active-
comparator group and tanezumab groups at both the 5 mg and
10 mg doses; individual and overall odds ratios for both studies
ranged from 0.79 to 1.07, with an overall odds ratio of 1.03.Table IV
Comparison of withdrawals due to AEs in tanezumab, tanezumab þ NSAID, placebo and
Study, year All anti-NGF groups Placebo
Withdrawals Subjects % Withdrawals Subjects %
Balanescu et al., 2013
Brown et al., 2012 23 516 4.5% 3 172 1.
Brown et al., 2013 20 466 4.3% 6 155 3.
Ekman et al., 2011 a 29 414 7.0% 7 208 3.
Ekman et al., 2011 b 18 420 4.3% 10 209 4.
Lane et al., 2010 22 370 5.9% 0 74 0.
Mayorga et al., 2014 6 98 6.1% 2 48 4.
Nagashima et al., 2011 0 67 0.0% 0 16 0.
Sanga et al., 2013 10 388 2.6% 1 78 1.
Schnitzer et al., 2014 151 1083 13.9%
Spierings et al., 2013 6 311 1.9% 2 141 1.
Tiseo et al., 2014 9 160 5.6% 2 55 3.
Total 294 4371 6.8% 33 1156 2.
* NSAID.
y DSR.
z Oxycodone.Comparison of the withdrawals due to AEs with regards to
tanezumab plus NSAID vs NSAID alone showed an overall odds
ratio of 1.91 (1.39, 2.61), favoring NSAID use alone. The incidence of
SAEs also favored NSAID use alone with an odds ratio of 1.39 (1.00,
1.94) for tanezumab plus NSAID compared to NSAID alone.
Whilewe did not quantitatively evaluate individual categories of
adverse effects, we did note an increase in the frequency of AEs
involving abnormalities of peripheral sensation (paresthesias, dys-
esthesia and others) that was reported with all three monoclonal
antibody therapies compared to placebo. No marked imbalance in
abnormalities possibly associated with the autonomic nervous
systemwas reported for any treatment.
Discussion
Summary of evidence and limitations
This systematic review includes data regarding three different
monoclonal antibodies that target NGF: tanezumab, fulranumab,
and fasinumab. Although these agents have been examined in
other pain states, including visceral pain35,36, back pain37,38,
neuropathic pain20 and cancer pain20, this review focuses on results
in studies of people with symptomatic OA, as the greatest number
of studies have been done for this clinical indication. At this time,
there are 10 separate studies of tanezumab, two with fulranumab
and one with fasinumab in OA. No new studies have been initiatedplacebo þ NSAID groups
All tanezumab þ Active comparator Placebo þ Active comparator
Withdrawals Subjects % Withdrawals Subjects %
28 452 6.2% y 6 152 3.9%
7%
9%
4% * 13 206 6.3%
8% * 16 211 7.6%
0%
2% z 14 50 28.0%
0%
3%
176 1078 16.3% * 49 539 9.1%
4% z 16 158 10.1%
6%
9% 204 1530 13.3% 114 1316 8.7%
Fig. 3. Withdrawals due to AEs; odds ratio [95% CI] by treatment groups.
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vestigations with anti-NFG antibodies in December, 2010, by the
FDA. Therefore, the bulk of the data evaluated at this time comes
from studies with tanezumab, and the focus of the review has
largely been on tanezumab with data from fulranumab and fasi-
numab included in order to provide complete information for this
class of biologics.
There have been two phase II studies of tanezumab reported and
ﬁve placebo-controlled phase III studies in OA. In addition, two
active-controlled phase III studies and one long-term efﬁcacy study
of tanezumab have been completed. Efﬁcacy with regard to all
three standard OA outcome measures (WOMAC pain subscale,
WOMAC function subscale, patient global assessment) was
observed in all of the placebo-controlled studies with one or more
doses of tanezumab. The stratiﬁcation of the phase II tanezumab
data into two groups, a lower dose group (10 mg/kg, 25 mg/kg, and
50 mg/kg) and a higher dose group (100 mg/kg and 200 mg/kg),
showed a signiﬁcant combined group difference. The phase III
tanezumab data showed no apparent heterogeneity between the
2.5 mg, 5 mg, and 10 mg subgroups with only small differences in
standardized effect size between the various dose groups.
The efﬁcacy of the highest doses from the phase II studies with
tanezumab demonstrated a greater standardized effect size than
observed in the high doses in the phase III studies. Tanezumab was
dosed in the phase II studies on a mg/kg basis whereas in phase III
standard dosing, in ﬁxed milligram amounts (2.5 mg, 5 mg and
10 mg), was administered. Thus, the 200 mg/kg dose for an 80 kg
individual would be 16 mg, considerably higher than the highest
10 mg dose in phase III. However, the 100 mg/kg dose would
represent 8 mg, which would be similar to the 10 mg dose in phase
III. Nevertheless the standardized effect size reported at 100 mg/kg
in the phase II studies was almost twice as great as that for the
10 mg dose studied in the phase III studies. At the lower doses, the
differences between the phase II and phase III arms were not
marked. The reason for this difference between the phase II and
phase III efﬁcacy data is not apparent as the protocols were similar
and the mean baseline WOMAC pain scores were actually some-
what higher in the phase III studies than in the phase II studies (7.3
vs 6.4, respectively, on a 11 point scale), contrary to what might
have been expected if response were positively correlated to
baseline pain. For fulranumab and fasinumab, limited phase II data
are available. Dose-dependent increases in efﬁcacy are suggestedwith both agents, though further studies may be required to deﬁne
an optimal dose for both efﬁcacy and safety.
Three trials compared tanezumab alone directly with two
different NSAIDs, celecoxib and naproxen, and one trial compared
tanezumab with oxycodone. In these studies, there was superiority
of tanezumab to the active comparators with a standardized effect
size only slightly less than that observed in the tanezumab vs
placebo trials. Additionally, two studies compared the efﬁcacy of
tanezumab combined with NSAID to NSAID therapy alone. In these
trials, tanezumab demonstrated additional efﬁcacy to NSAID alone,
themagnitude of whichwas similar to that observed for tanezumab
compared to placebo in the phase III trials.
To get an overall view of safety, we used the rate of withdrawal
due to AEs and the number of SAEs as outcome measures for
assessment. Studies with tanezumab and with the other two anti-
NGF monoclonal antibodies both reported a higher rate of with-
drawals due to AEs in the higher dose groups than in the placebo
groups, with odds ratios for withdrawal in the range of 1.3e1.5. In
contrast, the odds ratios for withdrawal at the lower dose ranges
were similar to that reported with placebo. No signiﬁcant differ-
ences were reported for SAEs between anti-NGF monoclonals and
placebo groups. Although not formally assessed, there were a
higher number of reports of abnormal peripheral sensation with
anti-NGF treatment compared to placebo for all agents.
A major limitation of this systematic review was the relatively
small number of studies, particularly placebo-controlled trials, at
various dose levels for each of the agents. The lack of additional
data limits the analyses that can be performed and conclusions to
be drawn. The strengths of this review is the quality of the studies
and the completeness of the data that were collected.
Conclusions
Inhibition of NGF by monoclonal antibodies has been demon-
strated to reduce the pain and increase the function and well-being
of individualswith symptomatic OA. This appears to be a class-effect
in that all three antibody preparations have reported efﬁcacy,
though additional replicate studies are required for a ﬁrm conclu-
sion with fulranumab and fasinumab. The optimal dose for clinical
use has not been deﬁned at this time for any of these therapies. For
tanezumab, higher doses have apparently greater efﬁcacy but are
also associated with a higher likelihood of AEs. The currently
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are associated with fewer AEs leading to study withdrawal than the
10 mg dose with no signiﬁcant difference in efﬁcacy.
The initial studies with tanezumab demonstrated a pain
response that was greater than typically reported for other non-
surgical therapies in OA. The magnitude of this response provides
evidence that inhibition of NGF-mediated processes is a potent
means of suppressing pain, and validates this mechanism in OA
pain. However, the appearance of untoward side effects, including
the high incidence of reversible abnormalities of peripheral
sensation, limited phase III studies to lower doses.With these doses
of tanezumab, efﬁcacy appears to be lower as is the incidence of
AEs. Whether higher doses of tanezumab may provide additional
efﬁcacy with adequate safety in other conditions, such as back pain
and possibly neuropathic pain, is not known but early studies20,37,38
have suggested signiﬁcant pain relief compared to placebo in these
conditions.
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